株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肝炎治療薬の世界市場:産業分析・市場規模・市場シェア・成長率・動向・予測

Hepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

発行 Transparency Market Research 商品コード 789633
出版日 ページ情報 英文 183 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
肝炎治療薬の世界市場:産業分析・市場規模・市場シェア・成長率・動向・予測 Hepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
出版日: 2019年01月22日 ページ情報: 英文 183 Pages
概要

当レポートでは、世界の肝炎治療薬の市場を調査し、市場および製品の概要、製品の投入・承認・特許失効の動向、パイプラインの分析、関連法規制、市場成長への各種影響因子および市場機会の分析、薬剤クラス・疾患区分・流通経路・地域/主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

第1章 序文

第2章 前提因子・調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
    • 成長推進因子
    • 成長抑制因子
    • 市場機会
  • 市場分析・予測
  • ポーターのファイブフォース分析

第5章 市場の展望

  • パイプライン分析
  • 製品の投入・承認・特許失効
  • 法規制シナリオ

第6章 世界の肝炎治療薬市場の分析・予測:疾患区分別

  • イントロダクション・定義
  • 市場規模の推移・予測
    • 肝炎 A
    • 肝炎 B
    • 肝炎 C
    • その他
  • 市場の魅力の分析

第7章 世界の肝炎治療薬市場の分析・予測:薬剤クラス別

  • イントロダクション・定義
  • 市場規模の推移・予測
    • ヌクレオチドアナログ逆転写酵素阻害剤
    • NS5A阻害剤
    • マルチクラス併用剤
    • ヌクレオチドアナログNS5Bポリメラーゼ阻害剤
    • インターフェロン&リバビリン
    • その他
  • 市場の魅力の分析

第8章 世界の肝炎治療薬市場の分析・予測:流通経路別

  • イントロダクション・定義
  • 市場規模の推移・予測流通経路別
    • 院内薬局
    • 小売薬局
    • オンライン薬局
  • 市場の魅力の分析

第9章 世界の肝炎治療薬市場の分析・予測:地域別

  • 市場規模の推移・予測
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力の分析

第10章 北米市場の分析・予測

  • イントロダクション
  • 市場予測:疾患区分別
  • 市場予測:薬剤クラス別
  • 市場予測:流通経路別
  • 市場予測:国別
  • 市場の魅力の分析

第11章 欧州市場の分析・予測

  • イントロダクション
  • 市場予測:疾患区分別
  • 市場予測:薬剤クラス別
  • 市場予測:流通経路別
  • 市場予測:国別
  • 市場の魅力の分析

第12章 アジア太平洋市場の分析・予測

  • イントロダクション
  • 市場予測:疾患区分別
  • 市場予測:薬剤クラス別
  • 市場予測:流通経路別
  • 市場予測:国別
  • 市場の魅力の分析

第13章 ラテンアメリカ市場の分析・予測

  • イントロダクション
  • 市場予測:疾患区分別
  • 市場予測:薬剤クラス別
  • 市場予測:流通経路別
  • 市場予測:国別
  • 市場の魅力の分析

第14章 中東・アフリカ市場の分析・予測

  • イントロダクション
  • 市場予測:疾患区分別
  • 市場予測:薬剤クラス別
  • 市場予測:流通経路別
  • 市場予測:国別
  • 市場の魅力の分析

第15章 競合環境

  • 企業シェア分析
  • 企業プロファイル
    • Gilead Sciences, Inc.
    • F. Hoffmann-La Roche, Ltd.
    • Bristol Myers Squibb
    • Merck & Co., Inc.
    • AbbVie Inc.
    • NATCO Pharma Limited
    • Zydus Cadila
    • Hetero Healthcare Limited
    • LAURUS Labs
    • Cipla, Inc.
図表

List of Tables

  • Table 01: Pipeline Analysis
  • Table 02: Pipeline Analysis
  • Table 03: Pipeline Analysis
  • Table 04: New Product Launch, Approvals & Patent Expiry
  • Table 05: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 - 2026 2016-2026
  • Table 06: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 - 2026
  • Table 07: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 08: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016-2026
  • Table 09: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 - 2026
  • Table 10: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 - 2026
  • Table 11: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 - 2026
  • Table 12: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 - 2026
  • Table 13: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 - 2026
  • Table 14: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 - 2026
  • Table 15: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 - 2026
  • Table 16: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 - 2026
  • Table 17: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 - 2026
  • Table 18: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 - 2026
  • Table 19: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 - 2026
  • Table 20: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 - 2026
  • Table 21: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 - 2026
  • Table 22: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 - 2026
  • Table 23: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 - 2026
  • Table 24: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 - 2026
  • Table 25: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 - 2026
  • Table 26: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 - 2026
  • Table 27: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 - 2026
  • Table 28: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 - 2026

List of Figures

  • Figure 01: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 02: Global Hepatitis Therapeutics Market Value Share (%), by Disease Type (2017)
  • Figure 03: Global Hepatitis Therapeutics Market Value Share (%), by Drug Class (2017)
  • Figure 04: Global Hepatitis Therapeutics Market Value Share (%), by Distribution Channel (2017)
  • Figure 05: Global Hepatitis Therapeutics Market Value Share (%), by Region (2017)
  • Figure 06: Global Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
  • Figure 07: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis A, 2016-2026
  • Figure 08: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis B, 2016-2026
  • Figure 09: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis C, 2016-2026
  • Figure 10: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016-2026
  • Figure 11: Global Hepatitis Therapeutics Market Attractiveness,, by Disease Type, 2018-2026
  • Figure 12: Global Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 13: Global Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018-2026
  • Figure 14: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleotide Analog Reverse Transcriptase Inhibitor, 2016-2026
  • Figure 15: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by NS5A Inhibitor, 2016-2026
  • Figure 16: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Multi-class Combination, 2016-2026
  • Figure 17: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleotide Analog NS5B Polymerase Inhibitor, 2016-2026
  • Figure 18: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Interferon & Ribavirin, 2016-2026
  • Figure 19: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016-2026
  • Figure 20: Global Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
  • Figure 21: Global Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 22: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016-2026
  • Figure 23: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016-2026
  • Figure 24: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016-2026
  • Figure 25: Global Hepatitis Therapeutics Market Value Share Analysis, by Region, 2018 and 2026
  • Figure 26: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Region, 2018-2026
  • Figure 27: North America Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 28: North America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 29: North America Hepatitis Therapeutics Market AttractivenessAnalysis, by Country, 2018-2026
  • Figure 30: North America Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
  • Figure 31: North America Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018-2026
  • Figure 32: North America Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 33: North America Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018-2026
  • Figure 34: North America Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
  • Figure 35: North America Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 36: Europe Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 37: Europe Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 38: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018-2026
  • Figure 39: Europe Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
  • Figure 40: Europe Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018-2026
  • Figure 41: Europe Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 42: Europe Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018-2026
  • Figure 43: Europe Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
  • Figure 44: Europe Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 45: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 46: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 47: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018-2026
  • Figure 48: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
  • Figure 49: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018-2026
  • Figure 50: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 51: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018-2026
  • Figure 52: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
  • Figure 53: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 54: Latin America Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 55: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 56: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018-2026
  • Figure 57: Latin America Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
  • Figure 58: Latin America Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018-2026
  • Figure 59: Latin America Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 60: Latin America Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018-2026
  • Figure 61: Latin America Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
  • Figure 62: Latin America Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 63: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016-2026
  • Figure 64: Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
  • Figure 65: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018-2026
  • Figure 66: Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
  • Figure 67: Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018-2026
  • Figure 68: Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
  • Figure 69: Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018-2026
  • Figure 70: Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
  • Figure 71: Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018-2026
  • Figure 72: Global Hepatitis Therapeutics Market Share, by Company, 2017
目次

Title:
Hepatitis Therapeutics Market (Disease Type - Hepatitis A, Hepatitis B, Hepatitis C; Drug Class - Nucleotide Analog Reverse Transcriptase Inhibitor, NS5A Inhibitor, Multi-class Combination, Nucleotide Analog NS5B Polymerase Inhibitor, Interferon and Ribavirin; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Global Hepatitis Therapeutics Market: Overview

This report analyzes the current and future scenario of the global hepatitis therapeutics market. Increase in the prevalence of viral hepatitis, promising hepatitis drug pipeline, and favorable government support are the major drivers of the global market.

The global hepatitis therapeutics market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to segments based on disease type, drug class, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises company profiles with product portfolio to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by region, and market share analysis, by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global hepatitis therapeutics market.

Global Hepatitis Therapeutics Market: Key Segments

The global hepatitis therapeutics market has been segmented based on disease type, drug class, distribution channel, and region. In terms of disease type, the global market has been segmented into hepatitis A, hepatitis B, hepatitis C, and others. Based on drug class, the global hepatitis therapeutics market has been categorized into nucleotide analog reverse transcriptase inhibitor, NS5A inhibitor, multi- class combination, nucleotide analog NS5B polymerase inhibitor, interferon & ribavirin, and others. Based on distribution channel, the global market has been divided into hospital pharmacies, retail pharmacies, and others. The market value and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Hepatitis Therapeutics Market: Regional Outlook

The global hepatitis therapeutics market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). The Market Value and forecast for each of these regions and countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global hepatitis therapeutics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, recent developments, and SWOT analysis. Major companies profiled in the report are Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., F. Hoffmann-La Roche, Ltd., LAURUS Labs, AbbVie Inc., Hetero Healthcare Limited, Zydus Cadila, Cipla, Inc., and NATCO Pharma Limited.

The global hepatitis therapeutics market has been segmented as below:

  • Global Hepatitis Therapeutics Market, by Disease
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Others
  • Global Hepatitis Therapeutics Market, by Drug Class
  • Nucleotide Analog Reverse Transcriptase Inhibitor
  • NS5A Inhibitor
  • Multi Class Combination
  • Nucleotide Analog NS5B Polymerase Inhibitor
  • Interferon & Ribavirin
  • Others
  • Global Hepatitis Therapeutics Market, by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Hepatitis Therapeutics Market, by Region
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Hepatitis Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Hepatitis Therapeutics Market Analysis and Forecasts, 2016-2026
    • 4.4.1. Market Revenue Projections (US$ Mn)
  • 4.5. Porter's Five Force Analysis

5. Market Outlook

  • 5.1.Pipeline Analysis
  • 5.2.New Product Launch, Approvals & Patent Expiry
  • 5.3.Regulatory Scenario

6. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Disease Type

  • 6.1. Introduction & Definition
  • 6.2. Market Value Forecast, by Disease Type, 2016-2026
    • 6.2.1. Hepatitis A
    • 6.2.2. Hepatitis B
    • 6.2.3. Hepatitis C
    • 6.2.4. Others
  • 6.3. Market Attractiveness, by Disease Type

7. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Drug Class

  • 7.1. Introduction & Definition
  • 7.2. Market Value Forecast, by Drug Class, 2016-2026
    • 7.2.1. Nucleotide Analog Reverse Transcriptase Inhibitor
    • 7.2.2. NS5A Inhibitor
    • 7.2.3. Multi Class Combination
    • 7.2.4. Nucleotide Analog NS5B Polymerase Inhibitor
    • 7.2.5. Interferon & Ribavirin
    • 7.2.6. Others
  • 7.3. Market Attractiveness, by Drug Class

8. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Market Value Forecast, by Distribution Channel, 2016-2026
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Retail Pharmacies
    • 8.2.3. Online Pharmacies
  • 8.4. Market Attractiveness, by Distribution Channel

9. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Region

  • 9.1. Market Value Forecast, by Region
    • 9.1.1. North America
    • 9.1.2. Europe
    • 9.1.3. Asia Pacific
    • 9.1.4. Latin America
    • 9.1.5. Middle East & Africa
  • 9.2. Market Attractiveness, by Country/Region

10. North America Hepatitis Therapeutics Market Analysis and Forecast

  • 10.1.Introduction
  • 10.2.Market Value Forecast, by Disease Type, 2016-2026
    • 10.2.1. Hepatitis A
    • 10.2.2. Hepatitis B
    • 10.2.3. Hepatitis C
    • 10.2.4. Others
  • 10.3.Market Value Forecast, by Drug Class, 2016-2026
    • 10.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
    • 10.3.2. NS5A Inhibitor
    • 10.3.3. Multi Class Combination
    • 10.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
    • 10.3.5. Interferon & Ribavirin
    • 10.3.6. Others
  • 10.4.Market Value Forecast, by Distribution Channel, 2016-2026
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5.Market Value Forecast, by Country, 2016-2026
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6.Market Attractiveness, Analysis
    • 10.6.1.By Disease Type
    • 10.6.2. B Drug Class
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Hepatitis Therapeutics Market Analysis and Forecast

  • 11.1.Introduction
  • 11.2.Market Value Forecast, by Disease, 2016-2026
    • 11.2.1. Hepatitis A
    • 11.2.2. Hepatitis B
    • 11.2.3. Hepatitis C
    • 11.2.4. Others
  • 11.3.Market Value Forecast, by Drug Class, 2016-2026
    • 11.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
    • 11.3.2. NS5A Inhibitor
    • 11.3.3. Multi-class Combination
    • 11.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
    • 11.3.5. Interferon & Ribavirin
    • 11.3.6. Others
  • 11.4.Market Value Forecast, by Distribution Channel, 2016-2026
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5.Market Value Forecast, by Country, 2016-2026
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6.Market Attractiveness, Analysis
    • 11.6.1. By Disease Type
    • 11.6.2. By Drug Class
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country

12. Asia Pacific Hepatitis Therapeutics Market Analysis and Forecast

  • 12.1.Introduction
  • 12.2.Market Value Forecast, by Disease Type, 2016-2026
    • 12.2.1. Hepatitis A
    • 12.2.2. Hepatitis B
    • 12.2.3. Hepatitis C
    • 12.2.4. Others
  • 12.3.Market Value Forecast, by Drug Class, 2016-2026
    • 12.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
    • 12.3.2. NS5A Inhibitor
    • 12.3.3. Multi-class Combination
    • 12.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
    • 12.3.5. Interferon & Ribavirin
    • 12.3.6. Others
  • 12.4.Market Value Forecast, by Distribution Channel, 2016-2026
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5.Market Value Forecast, by Country, 2016-2026
    • 12.5.1. Japan
    • 12.5.2. China
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6.Market Attractiveness, Analysis
    • 12.6.1. By Disease Type
    • 12.6.2. By Drug Class
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country

13. Latin America Hepatitis Therapeutics Market Analysis and Forecast

  • 13.1.Introduction
  • 13.2.Market Value Forecast, by Disease Type, 2016-2026
    • 13.2.1. Hepatitis A
    • 13.2.2. Hepatitis B
    • 13.2.3. Hepatitis C
    • 13.2.4. Others
  • 13.3.Market Value Forecast, by Drug Class, 2016-2026
    • 13.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
    • 13.3.2. NS5A Inhibitor
    • 13.3.3. Multi-class Combination
    • 13.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
    • 13.3.5. Interferon & Ribavirin
    • 13.3.6. Others
  • 13.4.Market Value Forecast, by Distribution Channel, 2016-2026
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5.Market Value Forecast, by Country, 2016-2026
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6.Market Attractiveness, Analysis
    • 13.6.1. By Disease Type
    • 13.6.2. By Drug Class
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country

14. Middle East & Africa Hepatitis Therapeutics Market Analysis and Forecast

  • 14.1.Introduction
  • 14.2.Market Value Forecast, by Disease Type, 2016-2026
    • 14.2.1. Hepatitis A
    • 14.2.2. Hepatitis B
    • 14.2.3. Hepatitis C
    • 14.2.4. Others
  • 14.3.Market Value Forecast, by Drug Class, 2016-2026
    • 14.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
    • 14.3.2. NS5A Inhibitor
    • 14.3.3. Multi-class Combination
    • 14.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
    • 14.3.5. Interferon & Ribavirin
    • 14.3.6. Others
  • 14.4.Market Value Forecast, by Distribution Channel, 2016-2026
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5.Market Value Forecast, by Country, 2016-2026
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.5. Rest of Middle East & Africa
  • 14.6.Market Attractiveness, Analysis
    • 14.6.1. By Disease Type
    • 14.6.2. By Drug Class
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country

15. Competition Landscape

  • 15.1.Market Share Analysis, by Company (2017)
  • 15.2. Company Profiles
    • 15.2.1. Gilead Sciences, Inc.
    • 15.2.2. F. Hoffmann-La Roche, Ltd.
    • 15.2.3. Bristol Myers Squibb
    • 15.2.4. Merck & Co., Inc.
    • 15.2.5. AbbVie Inc.
    • 15.2.6. NATCO Pharma Limited
    • 15.2.7. Zydus Cadila
    • 15.2.8. Hetero Healthcare Limited
    • 15.2.9. LAURUS Labs
    • 15.2.10. Cipla, Inc.
Back to Top